Cytosorbents investors anxious for European data |
![]() |
![]() |
By Patrick Crutcher | |
Friday, 28 January 2011 14:12 | |
![]() CytoSorbents is developing CytoSorb for the treatment of severe sepsis. CytoSorb is a hemoperfusion device(think, blood filter) that utilizes highly porous polymer beads designed to actively remove disease-causing substances from blood and physiologic fluids without reducing immune function. Specifically, the device is being used to reduce levels of cytokines, which can trigger dangerous inflammation and immune system responses. CTSO hopes that by reducing cytokines and other immunomodulators in sepsis patients, they can significantly improve their chances of survival. The device is highly compatible with standard hospital dialysis equipment. Typically, sepsis is associated with some type of infenction that eventually triggers an immune response releasing large levels of cytokines. Cytokines are important biological mediators that regulate immune and inflammatory responses. Oversecretion of cytokines can trigger a dangerous syndrome known as a cytokine storm, where excess cytokines can potentially do significant damage to body tissues and organs. (Cytokine storms were seen in numerous cases associated with H1N1 several years ago.) Sepsis effects roughly 18 million worldwide(with roughly 1.5 million cases in the European Union) and mortality rates around 30%. There are very limited treatment options for sepsis, most of which are only treating the infection, not the potentially deadly immune response. Current dialysis techniques have very little impact on filtering most cytokines. The last update from management noted that the study had enrolled 90 of 100 patients back in November 2010. We expect that this trial should be completed soon and for trial results to be made available soon after. To date, there has been no serious device-related adverse events in approximately 300 human treatments. They have seen very favorable trends in patients who were treated with their device. We look forward to seeing clinical results from their European study, as these results could map out a potentially bright future for this small company. We encourage investors to read a recent interview with CEO Dr. Phillip Chan and see their most recent corporate materials. Investors should consider the risk-reward profile here and position themselves accordingly. At $0.16, we like the potential for CTSO to demonstrate efficacy in severe sepsis. CTSO Investor Documents -- http://www.cytosorbents.com/invest.htm ![]() "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |